ArticleThe Lancet. Global health2019
World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions.
Article in The Lancet. Global health, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 612 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Bromocriptine in Dilated Cardiomyopathy in Women of Reproductive Age: A Hospital-Based Randomized Open Label Placebo-controlled Clinical Trial
Bempedoic Acid in Primary Percutaneous Coronary Intervention: Impact on Inflammatory Markers, Procedural and Clinical Outcomes
Who cites it
612 citing papers in PubMed, 9 syntheses or guidelines pooled it, 1,133 citations in OpenAlex.
- Pharmacological lipid-lowering therapies for primary and secondary prevention of cardiovascular disease in adults with dyslipidaemia: a systematic review and network meta-analysis.The Cochrane database of systematic reviews · 2026Pooled it
- Pooled it
- Associations between phosphodiesterase type 5 inhibitors and vascular function: a systematic review and meta-analysis on randomized-controlled trials.Systematic reviews · 2025Pooled it
- Hypertension Canada guideline for the diagnosis and treatment of hypertension in adults in primary care.Canadian family physician Medecin de famille canadien · 2025Guideline
- Guideline
- Hypertension Canada guideline for the diagnosis and treatment of hypertension in adults in primary care.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2025Guideline
- Dyslipidemia and associated factors among hypertensive patients in Ethiopia: a systematic review and meta-analysis.BMC cardiovascular disorders · 2025Pooled it
- Discrimination and calibration performances of non-laboratory-based and laboratory-based cardiovascular risk predictions: a systematic review.Open heart · 2025Pooled it
- RETRACTED: Cardiovascular and mortality outcomes of DPP-4 inhibitors vs. sulfonylureas as metformin add-on therapy in patients with type 2 diabetes: A systematic review and meta-analysis.PloS one · 2025 · on this mapPooled it
- Community health worker-led versus facility-based type 2 diabetes care in rural Lesotho: a cluster-randomized trial within the ComBaCaL cohort study.BMC medicine · 2026 · on this mapTrial
- Effect of Tai Chi Yunshou motor imagery training on upper limb motor dysfunction with stroke patients.BMC complementary medicine and therapies · 2026Trial
- Effectiveness of a WeChat Mini Program-Based Intervention on Promoting Multiple Health Behavior Changes Among Chinese Patients With Cardiovascular Diseases in Home-Based Rehabilitation: Randomized Controlled Trial.Journal of medical Internet research · 2025Trial
- When Risk Scores Disagree: Rethinking Cardiovascular Risk Prediction in South Asians.JACC. Asia · 2026Article
- Comparison of ASCVD Risk Prediction Models in STEMI: Insights From a South Asian Cohort.JACC. Asia · 2026Article
- A multicentre evaluation of cardiovascular risk prediction tools in people living with HIV across England (ECARTH study).HIV medicine · 2026Observational
- Cardiovascular Risk Assessment Tools in CKD.Clinical journal of the American Society of Nephrology : CJASN · 2026Review
- Service delivery interventions for lipid testing and lipid-lowering therapy for primary and secondary prevention of cardiovascular disease in adults.The Cochrane database of systematic reviews · 2026Article
- Global Research Trends and Insights on AI Usage in Tuberculosis: Bibliometric Analysis.JMIR medical informatics · 2026Article
- Prediction of incident heart failure in individuals without prior cardiovascular disease: the SCORE2-HF risk model.European heart journal · 2026Article
- Heart failure may promote breast cancer progression through a Col10a1-associated Tgf-β/Smad-EMT pathway.Biology direct · 2026Article
552 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
1 author at 3 institutions in 3 countries.
Funding
Abstract
backgroundTo help adapt cardiovascular disease risk prediction approaches to low-income and middle-income countries, WHO has convened an effort to develop, evaluate, and illustrate revised risk models. Here, we report the derivation, validation, and illustration of the revised WHO cardiovascular disease risk prediction charts that have been adapted to the circumstances of 21 global regions.
methodsIn this model revision initiative, we derived 10-year risk prediction models for fatal and non-fatal cardiovascular disease (ie, myocardial infarction and stroke) using individual participant data from the Emerging Risk Factors Collaboration. Models included information on age, smoking status, systolic blood pressure, history of diabetes, and total cholesterol. For derivation, we included participants aged 40-80 years without a known baseline history of cardiovascular disease, who were followed up until the first myocardial infarction, fatal coronary heart disease, or stroke event. We recalibrated models using age-specific and sex-specific incidences and risk factor values available from 21 global regions. For external validation, we analysed individual participant data from studies distinct from those used in model derivation. We illustrated models by analysing data on a further 123 743 individuals from surveys in 79 countries collected with the WHO STEPwise Approach to Surveillance.
findingsOur risk model derivation involved 376 177 individuals from 85 cohorts, and 19 333 incident cardiovascular events recorded during 10 years of follow-up. The derived risk prediction models discriminated well in external validation cohorts (19 cohorts, 1 096 061 individuals, 25 950 cardiovascular disease events), with Harrell's C indices ranging from 0·685 (95% CI 0·629-0·741) to 0·833 (0·783-0·882). For a given risk factor profile, we found substantial variation across global regions in the estimated 10-year predicted risk. For example, estimated cardiovascular disease risk for a 60-year-old male smoker without diabetes and with systolic blood pressure of 140 mm Hg and total cholesterol of 5 mmol/L ranged from 11% in Andean Latin America to 30% in central Asia. When applied to data from 79 countries (mostly low-income and middle-income countries), the proportion of individuals aged 40-64 years estimated to be at greater than 20% risk ranged from less than 1% in Uganda to more than 16% in Egypt.
interpretationWe have derived, calibrated, and validated new WHO risk prediction models to estimate cardiovascular disease risk in 21 Global Burden of Disease regions. The widespread use of these models could enhance the accuracy, practicability, and sustainability of efforts to reduce the burden of cardiovascular disease worldwide.
fundingWorld Health Organization, British Heart Foundation (BHF), BHF Cambridge Centre for Research Excellence, UK Medical Research Council, and National Institute for Health Research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.